Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
ESMO Open|August 21, 2025
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validationH R Howard, M Hasanova, A Tiwari, et al.
ESMO Open|November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14L Frehner, S Schär, S Hayoz, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
ESMO Open|July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14D König, S Savic Prince, S Hayoz, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trialR A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 2